Home > Research Areas > Cancer > Ovarian Cancer
Cat. No. Product name CAS No.
DC11641 Cridanimod Featured

A potent type I interferon (IFN) inducer that directly binds to STING and triggers a strong antiviral response through the TBK1/IRF3 route.

38609-97-1
DC1022 ABT-737 Featured

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM, respectively.

852808-04-9
DC7363 AT-406 Featured

AT-406 (formerly known as SM-406) is an orally bioavailable potent IAP (inhibitor of apoptosis protein) of XIAP, cIAP1, and cIAP2 with Ki of 66.4 nM, 1.9 nM, and 5.1 nM, respectively.

1071992-99-8
DC3170 Cediranib

Cediranib (AZD2171) is a highly potent VEGFR2 inhibitor with IC50 of 0.5 nM, also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM.

288383-20-0
DC10657 COTI-2 Featured

COTI-2 is a small molecule candidate anti-cancer drug which can convert mutant p53 to wild-type conformation.

1039455-84-9
DC11642 Cridanimod sodium Featured

Cridanimod sodium is a potent type I interferon (IFN) inducer that directly binds to STING and triggers a strong antiviral response through the TBK1/IRF3 route.

58880-43-6
DC3156 Elesclomol (STA-4783) Featured

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that illicits pro-apoptosis events among tumor cells..

488832-69-5
DC7140 GSK1070916 Featured

GSK1070916 is a reversible and ATP-competitive inhibitor of Aurora B/C with IC50 of 3.5 nM/6.5 nM; displays >100-fold selectivity against the closely related Aurora A-TPX2 complex(IC50=490 nM).

942918-07-2
DC8630 Ralimetinib 2MsOH(LY2228820)

LY2228820 is a novel and potent p38MAPK inhibitor (the IC50 for p38αMAPK and p38βMAPK were 7 nM and 3 nM, respectively).

862507-23-1
DC7191 LY-2940680(Taladegib)

LY2940680 binds to the Smoothened (Smo) receptor and potently inhibits Hedgehog (Hh) signaling.

1258861-20-9
DC4179 Niraparib(MK4827) free base Featured

MK-4827 is an inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity.

1038915-60-4
DC9862 Niraparib(MK4827) hydrochloride Featured

MK-4827 is an inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity.

1038915-64-8
DC9576 Niraparib(MK-4827) tosylate Featured

MK-4827(Niraparib) tosylate is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM; with great activity in cancer cells with mutant BRCA-1 and BRCA-2; >330-fold selective against PARP3, V-PARP and Tank1.

1038915-73-9
DC4110 AZD-2281 (Olaparib) Featured

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1 and PARP2 with IC50 of 5 nM and 1 nM, respectively.

763113-22-0
DC10054 Ombrabulin hydrochloride Featured

Ombrabulin (AVE8062) hydrochloride is a synthetic derivative of CA-4-P, which inhibits growth in a large number of drug-resistant animal tumors and carcinogen-induced tumors.

253426-24-3
DC11203 ORIC-101

ORIC-101 (ORIC101) is a highly potent, selective steroidal glucocorticoid receptor (GR) antagonist (IC50=5.6 nM) with reduced androgen receptor (AR) agonistic activity.

2222344-98-9
DC10070 PRIMA-1MET(APR-246) Featured

PRIMA-1MET is methylated derivative of PRIMA-1. It can restore mutant p53 activity.

5291-32-7
DC5151 Rucaparib phosphate (AG-14699, PF-01367338) Featured

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM with binding affinity to nine PARP domains. Phase 1/2.

459868-92-9
DC8464 Rucaparib(AG-014447) Featured

Rucaparib inactivates PARP activity in cells with homologous recombination DNA repair pathway mutations at LC50 values ranging from 1.3-5.5 μM.

283173-50-2
DC7769 Tanomastat

Tanomastat is an angiogenesis and Matrix Metalloproteinase inhibitor

179545-77-8
DC10611 Trabectedin Featured

Trabectedin (Ecteinascidin-743 or ET-743) is a novel antitumour agent of marine origin with potent antitumour activity both in vitro and in vivo.

114899-77-3
DC7522 Triapine Featured

Triapine is a potent ribonucleotide reductase inhibitor with broad spectrum antitumor activity by inhibiting DNA synthesis. Phase 2.

143621-35-6
Page 1 / Total 2 FirstPrevNextLastGoto